In clinical trials, precision alone isn’t enough. Clients need clarity, confidence, and a team they can rely on. This article explains how Agilex delivers client-centric bioanalysis through tailored engagement, dedicated leads, and transparent collaboration.
Oligonucleotide therapeutics are transforming modern medicine, but analysing them is anything but simple. This article breaks down the three core challenges of oligonucleotide bioanalysis and the regulatory-ready LC-MS strategies required to generate reliable, submission-quality data.
Agilex Biolabs expands with a new Flow Cytometry Laboratory at QIMR Berghofer, boosting speed and precision in clinical research.
Contracted by the South Australian Government, Agilex Biolabs is deploying world-class science to sa...
Introduction – A New Chapter in Drug Development The use of biomarkers in medicine is not new....
By Dr Hayley Kain, Pharmacokinetic Scientist at Agilex Biolabs Rapid Data. Smarter Decisions. No...
By Dr. Kurt Sales, CSO Section Summary: How Agilex has emerged as a leader to support the ris...
By Dr. Kurt Sales, CSO Summary The following article focuses on the use of flow cytometry in c...
By William Grenfell, Head of IT In today's digital age, information security is paramount. At Agi...
By Kim Salvatore, Head of Client and Operational Services The bioanalytical and drug development...
Research shows that Biotechnology companies have been facing significant challenges – with continu...
By Dr. Kurt Sales, CSO Introduction Immunological assays are essential in drug development, es...
